A randomized, active-comparator-controlled, multicenter study to assess the safety and efficacy of different doses of BAY 1213790 for the prevention of venous thromboembolism in patients undergoing elective primary total knee arthroplasty, open-label to treatment and observer-blinded to BAY 1213790 doses

Trial Profile

A randomized, active-comparator-controlled, multicenter study to assess the safety and efficacy of different doses of BAY 1213790 for the prevention of venous thromboembolism in patients undergoing elective primary total knee arthroplasty, open-label to treatment and observer-blinded to BAY 1213790 doses

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs BAY 1213790 (Primary) ; Apixaban; Enoxaparin sodium
  • Indications Venous thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms FOXTROT
  • Sponsors Bayer
  • Most Recent Events

    • 10 Oct 2017 Status changed from not yet recruiting to recruiting.
    • 27 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top